Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that mediate and/or modulate synaptic transmission in the nervous system. [1] [2] [3] In mammalian brain, neuronal nAChR subunits are identified as a2-a7, a9, a10, and b 2-b 4. 4, 5) Ligand-binding studies indicate that the most abundant native nAChRs in the central nervous system are a4b 2 heteromeric receptors and a7 homomeric receptors.
A variety of alkaloids were isolated from amphibian skins, including indolizidines, quinolizidines, decahydroquinolines and piperidines, some of which have been identified as noncompetitive blockers of nAChRs at neuromuscular junction and in ganglionic PC12 cells 14) and recombinant neuronal nAChRs expressed in Xenopus oocytes. 15) To date, a wide range of toxins, including different types of decahydroquinolines and quinolizidines, have been isolated from ascidians (tunicates, subphylum Urochordata, class Ascidiacea) commonly known as sea squirts. 16) Nevertheless, none of the ascidian alkaloids has been tested in pharmacological research to develop therapeutically useful nicotinic drugs. Previously, we have redefined the absolute configuration of two ascidian alkaloids by enantioselective total synthesis: (Ϫ)-pictamine, a quinolizidine alkaloid from Clavelina picta, and (Ϫ)-lepadin B, a decahydroquinoline alkaloid from Clavelina lepadiformis. In the present study, we investigated the effects of (Ϫ)-pictamine and (Ϫ)-lepadin B on the major types of nicotinic receptors (a4b 2 and a7) expressed in Xenopus oocytes.
MATERIALS AND METHODS

Materials
All alkaloids used in this study were synthesized and are shown in Fig. 1 . The synthesis of (Ϫ)-pictamine and (Ϫ)-lepadin B was performed as reported previously. 17, 18) The 3-piperidinol alkaloid (+)-prosafrinine, originally isolated from the leaves of Prosopis africana, has also been synthesized as described previously.
19) The structures of these alkaloids are identical to those of the natural products. The other reagents were purchased from Sigma (St. Louis, MO, U.S.A.), unless indicated otherwise.
Expression in Xenopus Oocytes
To assess the nAChR activity, we measured current through the receptor-channel following the techniques described in detail by Tsuneki et al. 15) In brief, oocytes were isolated from Xenopus laevis frogs and were microinjected with 20 ng cDNAs in the nucleus. The mixture of cDNAs of mouse a4 and mouse b 2 subunits was injected in a ratio of 1 : 1, whereas mouse a7 cDNA was injected alone. Oocytes were used in electrophysiological recordings 3 to 8 d after the injection. All experiments were carried out in accordance with guidelines approved by the Toyama Medical and Pharmaceutical Univer-sity Animal Research Committee.
Electrophysiological Recording An oocyte was placed in a 300-ml tube-like chamber in which a low-Ca 2ϩ Ringer's solution (82.5 mM NaCl, 2.5 mM KCl, 0.5 mM CaCl 2 , 2 mM MgCl 2 , and 5 mM HEPES, pH 7.4) containing 1 mM atropine to block endogenous muscarinic receptors was perfused by gravity (15 ml/min). The low-Ca 2ϩ Ringer's solution is used to prevent strong activation of the endogenous calcium-dependent chloride conductance. 20) Current responses were recorded under two-electrode voltage-clamp at a holding potential of Ϫ60 mV using a GeneClamp 500 amplifier and pClamp7 software (Axon Instruments, Union City, CA, U.S.A.). The sampling rate was 20 Hz. Electrodes contained 3 M KCl and had resistances of Ͻ1 MW. The rapid solution exchange was performed by a computer-controlled three-way Teflon solenoid valve (Parker Hannifin Corp., Division of General Valve, NJ, U.S.A.). Curve fittings to the concentration-inhibition curves for alkaloids (antagonists) and to the ACh concentration-response curves were performed as described previously. 15) 
RESULTS
Concentrations near the 30% effective doses (EC 30 ) of ACh were used to elicit the currents, that is, 1 mM for a4b 2 receptors and 100 mM for a7 receptors. The a4b 2 currents were inhibited by dihydro-b -erythroidine (the best characterized antagonist of a4b 2 receptors, 5 mM) and a7 currents were inhibited by methyllycaconitine (a selective antagonist of a7 receptors, 10 nM) as reported previously. 15) When the oocytes expressing a4b 2 or a7 receptors were preincubated with (Ϫ)-pictamine (3 mM) for 3 min, the peak amplitude of currents elicited by ACh (1 mM for a4b 2 receptors, 100 mM for a7 receptors) was markedly decreased ( Fig. 2A) . Interestingly, no recovery was observed after the removal of (Ϫ)-pictamine in oocytes expressing a4b 2 receptors, whereas the inhibited a7 currents completely recovered 12 min after the removal of (Ϫ)-pictamine. To quantitatively assess this profile, the oocytes expressing a4b 2 receptors were stimulated with ACh pulses (1 mM, 5 s) at indicated times (Fig. 2B ). In the absence of the alkaloid, repeatable, constant currents were obtained. (Ϫ)-Pictamine (3 mM) caused a timedependent blockade of the a4b 2 currents, and the degree of blockade was maintained at least 48 min after the washout of (Ϫ)-pictamine (Fig. 2B ). These results suggest that the rate of dissociation of (Ϫ)-pictamine is extremely different between a4b 2 and a7 receptors. To compare the potency of (Ϫ)-pictamine on a4b 2 and a7 currents, the peak amplitude of the currents was measured after 3 min of the alkaloid incubation. We observed that (Ϫ)-pictamine blocked the currents in a concentration-dependent manner, with IC 50 values of 1.5 mM for a4b 2 currents and 1.3 mM for a7 currents (Figs. 2C, D, Table 1 ). Thus, (Ϫ)-pictamine equally blocks a4b 2-and a7-nAChRs. As shown in Fig. 2E , the concentration-response relationship for ACh on a7 receptors was fit by a single Hill equation (EC 50 ϭ158 mM, Hill coefficient nHϭ1.31). The ACh concentration-response curve shifted downward in the presence of (Ϫ)-pictamine (3 mM) (Fig. 2E ), indicating that (Ϫ)-pictamine is not a competitive blocker of a7 receptors.
When the oocytes expressing a4b 2 receptors were preincubated with (Ϫ)-lepadin B (3 mM) for 3 min, the peak amplitude of currents elicited by ACh (1 mM) was greatly decreased (Fig. 3A) . This blocking effect was reversible within 9 min. Similar reversible blockade was observed in ACh (100 mM)-elicited currents in oocytes expressing a7 receptors. In fact, these currents were blocked by this alkaloid in a concentration-dependent manner, with IC 50 values of 0.9 mM for a4b 2 currents and 0.7 mM for a7 currents (Figs. 3B, C, Table 1 ). Thus, (Ϫ)-lepadin B appears to equally block a4b 2-and a7-nAChRs. Furthermore, as shown in Fig. 2E , the concentration-response curve for ACh on a7 receptors shifted downward in the presence of (Ϫ)-lepadin B (1 mM), and the responses to ACh at the maximal concentrations (3 and 10 mM) did not reach the levels observed in the absence of (Ϫ)-lepadin B. These results indicate that (Ϫ)-lepadin B is not a competitive blocker of a7 receptors.
We further examined the effect of (+)-prosafrinine on the ACh-elicited currents because the 3-hydroxy piperidine moiety is a structure that (Ϫ)-lepadin B and (+)-prosafrinine have in common. When the oocytes expressing a4b 2 or a7 receptors were preincubated with (+)-prosafrinine for 3 min, the peak amplitude of currents elicited by ACh (1 mM for a4b 2 receptors, 100 mM for a7 receptors) was markedly blocked: the IC 50 values for a4b 2 and a7 receptors were 2.9 mM and 1.1 mM, respectively (Table 1) .
DISCUSSION
In the present study, we found that ascidian alkaloids (Ϫ)-pictamine and (Ϫ)-lepadin B are potent blockers of a4b 2-and a7-nAChRs. Moreover, it is interesting that no recovery of a4b 2 currents was observed after the removal of (Ϫ)-pictamine, whereas the inhibited a7 currents quickly recovered after its removal. It is possible that "treatment and washout" of (Ϫ)-pictamine would effectively remove the a4b 2-nAChR action from neuronal activities mediated mainly by a4b 2 and a7 receptors, such as dopaminergic neuron activities in mouse ventral tegmental area and substantia nigra pars compacta. 21) Further studies are, however, required to determine the selectivity of (Ϫ)-pictamine for a4b 2 receptors over several other subtypes of nAChRs, including muscle-type nAChRs. Thus, this study is the first report indicating that natural products derived from ascidians may be an overlooked source for the discovery of novel nicotinic ligands. The present results demonstrate that (Ϫ)-pictamine is a noncompetitive blocker of a7-nAChR, although the mechanisms underlying the long-term inhibition of a4b 2-nAChR remains unclear. Typical noncompetitive blockers are channel blockers, whereas a few drugs, such as steroids, act noncompetitively (allosterically) at extracellular sites to inhibit nAChR function. 9) Several high affinity binding sites for the channel blockers have been found to be located in the walls of the ion channel, which are made up of transmembrane segments M2. 22) The amino acid sequences in and around M2 segments are very similar, but still not identical among a4, b 2 and a7 nicotinic subunits. 22, 23) Since the lining of the ion channels is considered to be one of the most plausible binding sites of (Ϫ)-pictamine, we suggest that the diversity in the amino acid sequences may affect the stability of binding to each receptor subtype. We could not, however, exclude alternative possibility that (Ϫ)-pictamine irreversibly binds to the ACh-binding sites or their vicinity on a4b 2-nAChR, and blocks the receptor activation. The snake toxin a-bungarotoxin is a specific and almost irreversible antagonist of a7-nAChR.
24) Based on these properties, a-bungarotoxin covalently linked to a resin is used for affinity chromatography to purify the a7 receptor protein. 25) Since there are few irreversible antagonists of a4b 2 receptors, (Ϫ)-pictamine will be a novel, valuable tool to study the properties and functions of a4b 2-nAChR.
Lepadin B has a unique structure, 2,5-disubstituted-3-hydroxy-decahydroquinoline. A number of 2,5-disubstituted decahydroquinolines have been isolated from skin extracts from dendrobatid frogs, 14) but no alkaloids from the frog skins have been classified as 2,5-disubstituted-3-hydroxydecahydroquinolines. Since there is a 3-hydroxy piperidine moiety in the structure of lepadin B, we further examined the effect of a 2,6-disubstituted-3-hydroxy-piperidine analog, (ϩ)-prosafrinine, and found that it blocks both a4b 2-and a7-nAChRs. From the frog alkaloids, no such analog has been found (but 2,6-disubstituted-4-hydroxy-piperidine 241D that is a potent noncompetitive blocker of neuromuscular and ganglionic-types of nAChRs), 14) and, to our knowledge, this is the first report demonstrating the blocking effect of the 3-hydroxylated piperidine on nAChRs. Although more detailed studies are required using other compounds of similar structure, the result suggests that the 3-hydroxy piperidine moiety of lepadin B may be an important structure for the interact with these nAChRs types. In addition, we consider that the 2,5-disubstituted decahydroquinoline moiety may also be a key structure for the biological activity of lepadin B, because several 2,5-disubstituted decahydroquinoline alkaloids, such as cis-195A, are reported to cause noncompetitive blockade of muscle-type nAChRs at the neuromuscular junction and ganglionic-type nAChRs in PC12 cells. 14) Similarly, lepadin B is predicted to be a noncompetitive blocker of several subtypes of nAChRs, including muscle-type nAChRs, and these pharmacological profiles needs to be elucidated in a future study.
Naturally occurring toxins are thought to be used by the sea squirts for chemical defense. 26) It has been reported that lepadin B elicits cytotoxic effects with IC 50 values of 44 mM for human brest cancer MCF7, 26 mM for glioblastoma U373, and 38 mM for ovarian carcinoma HEY cells. 27) However, these toxic concentrations are 30-to 60-fold higher than the IC 50 values of (Ϫ)-lepadin B for blockade of the nAChRs expressed in oocytes (Table 1) . In fact, the blocking effect of (Ϫ)-lepadin B was reversible and reproducible in the same oocytes (data not shown). Moreover, no changes in the holding current were observed during the application of (Ϫ)-lepadin B (data not shown). Therefore, it is not likely that (Ϫ)-lepadin B damages oocytes in the present condition.
Recent genetic studies demonstrate that autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE) is associated with a mutation in the a4 or the b 2 subunit of nAChRs. 9) The mutant nAChR expressed in Xenopus oocytes exhibits an increased sensitivity to ACh. A promising therapeutic strategy suggested for ADNFLE is to reduce the enhanced responses of the mutant a4b 2-nAChRs by noncompetitive nicotinic antagonists (open channel blockers). That type of blocker could selectively target the receptors displaying a gain of function by blocking them in a use-dependent manner. 9 ) Although (Ϫ)-pictamine does not appear to be an usedependent blocker, its longer-term inhibition suggests that further studies of ascidian alkaloids could reveal beneficial developments for nicotinic-based treatment of neurological diseases.
